Gi-Biome
Gi-Biome is a South Korean biotechnology company founded in 2018 that conducts research and development on intestinal immune system and microbiome combination treatments, operating from Seongnam with limited publicly disclosed operational details.
- Company typePrivate
- Founded2018
- HeadquartersSeongnam, South Korea
- Headcount1–10
- GTM typeB2B
- OfferingServices
Gi-Biome firmographics
Firmographics- Name
- Gi-Biome
- Website
- https://gi-biome.com
- Company type
- Private
- Founded year
- 2018
- Headcount range
- 1–10 employees
- Short description
- Gi-Biome is a South Korean biotechnology company founded in 2018 that conducts research and development on intestinal immune system and microbiome combination treatments, operating from Seongnam with limited publicly disclosed operational details.
- Ownership category
- akta.pro rank
Gi-Biome industry classification
Industry- Product category
- Microbiome Therapeutics R&D
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK)
- akta.pro secondary industries
- Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD), Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH)
Keywords
Where Gi-Biome is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Markets served
Gi-Biome business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Gi-Biome product offering
Product offeringCore offering
Gi-Biome is a for-profit biotechnology research and development company that focuses on the intestinal immune system and the microbiome, working on combination treatments that integrate these two domains. The company conducts R&D activities aimed at developing novel therapeutic approaches for gut-related health conditions. Founded in 2018 and headquartered in Seongnam, South Korea.
Differentiator
Problem solved
Functional benefit
Products and services
- Intestinal Immune System and Microbiome Combination Treatment R&D Research and development services focused on combination treatments that integrate the intestinal immune system and the microbiome. The offering is targeted at pharmaceutical, biotech, and research partners seeking novel therapeutic approaches in gut health.
Companies that use Gi-Biome
Customer profileIdeal customer profiles1 record
Gi-Biome technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Gi-Biome competitors and assessment
Company assessmentBroad incumbents
- Rebiotix (Ferring Pharmaceuticals): Rebiotix pioneered FDA-approved microbiome therapy RBX2660 (now Ferring's REBYOTA) for recurrent C. difficile. As a Ferring unit it is a broad-incumbent in live biotherapeutics with overlapping GI focus.
Emerging players
- BIOHM Health: US-based microbiome company combining fungal and bacterial therapeutics research, reflecting the broader microbiome-immune R&D model Gi-Biome pursues, albeit at earlier translational maturity.
- Assembly Biosciences: Clinical-stage company developing microbiome-based and antiviral therapies; emerging overlap with Gi-Biome through microbiome programs targeting GI and immune-related conditions.
- Da Volterra: France-based biotech developing microbiome-protective therapeutics to prevent antibiotic-induced dysbiosis and CDI. Relevant as a European emerging peer in microbiome-focused GI therapeutic development.
Direct peers
- MaaT Pharma: European clinical-stage microbiome therapeutics company with MaaT013 for GI graft-versus-host disease. Comparable as a focused microbiome-GI therapeutics developer.
- Enterome: Microbiome-derived drug developer focused on GI inflammation and immuno-oncology, with both small-molecule and microbial approaches relevant to Gi-Biome's combination-treatment concept.
- 4D pharma: UK-based microbiome therapeutics company developing single-strain and multi-strain live biotherapeutics across oncology, GI, and respiratory indications.
- Second Genome: Microbiome R&D company leveraging microbiome-immune science for therapeutic discovery, comparable to Gi-Biome on platform-driven microbiome-immune R&D.
- Seres Therapeutics: Pioneer in microbiome therapeutics with SER-109 approved for recurrent C. difficile infection and additional GI programs. Operates in the same therapeutic area with overlapping mechanism ambitions.
- Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined consortia of bacteria for GI and immune-mediated indications. Direct comparator to Gi-Biome on the microbiome-immune mechanism axis.
Market position
Customer concentration
Gi-Biome financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gi-Biome leadership team
Management profileNumber of profiles
Profiles1 record
Gi-Biome funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gi-Biome M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gi-Biome
What does Gi-Biome do?
Gi-Biome is a for-profit biotechnology research and development company that focuses on the intestinal immune system and the microbiome, working on combination treatments that integrate these two domains. The company conducts R&D activities aimed at developing novel therapeutic approaches for gut-related health conditions. Founded in 2018 and headquartered in Seongnam, South Korea.
When was Gi-Biome founded?
Gi-Biome was founded in 2018. It employs 1 to 10 people.
Where is Gi-Biome based?
Gi-Biome is headquartered in Seongnam, South Korea, in the Asia region.
Who are Gi-Biome's main competitors?
Rebiotix (Ferring Pharmaceuticals) is listed as a broad incumbent. Emerging players are BIOHM Health, Assembly Biosciences and Da Volterra. Direct peers are MaaT Pharma, Enterome, 4D pharma, Second Genome, Seres Therapeutics and Vedanta Biosciences.
Does Gi-Biome have an API?
No public API is recorded for Gi-Biome.
What industry is Gi-Biome in?
Gi-Biome's product category is Microbiome Therapeutics R&D. Its primary akta.pro industry code is HLAAAFAK, Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling), with a secondary code of HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits). Its NAICS code is 541714 and its SIC code is 2836.